CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: • as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. • in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. • in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. • as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of CYRAMZA (Ramucirumab) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the CYRAMZA (Ramucirumab) medicine cost price in India.
The order for CYRAMZA (Ramucirumab) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Ramucirumab is used to treat stomach cancer, colorectal cancer, or non-small cell lung cancer that has spread to other parts of the body. Ramucirumab may be given alone or in combination with other cancer medicines.
CYRAMZA (ramucirumab) injection, for intravenous use. Initial U.S. Approval: 2014
Generic Name: Ramucirumab
Injection: 100 mg/10 mL (10 mg/mL) or 500 mg/50 mL (10 mg/mL) solution in a single-dose vial.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand CYRAMZA (Ramucirumab) on prescription and Import License in Patient's Name only.
For overseas patients, CYRAMZA (Ramucirumab) can be made available in Send your enquiry to find CYRAMZA (Ramucirumab) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For CYRAMZA (Ramucirumab) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer For More Details
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma For More Details